FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
Name and Address of Reporting Person * Lam Thomas S.					2. Issuer Name and Ticker or Trading Symbol Apollo Medical Holdings, Inc. [AMEH]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) 1668 S. GARFIELD AVENUE, 2ND FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 06/11/2019							X_Off	X Officer (give title below) Other (specify below) Chief Executive Officer				
(Street) ALHAMBRA, CA 91801				4. If Amendment, Date Original Filed(Month/Day/Year)							n/Day/Year)	_X_ Form	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqu							uired, Dis	ired, Disposed of, or Beneficially Owned				
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	Execu			(Instr. 8)		4. Securities (A) or Dispo		Disposed	of (D) Benefic Reporte	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form:	Beneficial	
				(Month/Day/Year)			ode	V	Amoun	(A) or t (D)	Price	(Instr. 3	and 4)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common	Stock		06/11/2019]	P		6,900	I A	\$ 14.6	1,657,	540		D	
			Table II -					quire	the f d, Di	orm dis	splays a	curr nefici	ently vali	quired to res d OMB con d	•		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transactic Date (Month/Day	on 3A. Deemed Execution Da	ate, if	4. Transact Code	ion	5.	rative rities ired rosed) . 3, 15)	6. Dand (Mo	ate Exer Expirationth/Day/	on Date	7. An Un See (In 4)	Title and mount of nderlying curities astr. 3 and		9. Number Derivative Securities Beneficiall Owned Following Reported Transaction (Instr. 4)	Owners. Form of Derivati Security Direct (or Indire	Beneficial Ownershi (Instr. 4)

Reporting Owners

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Lam Thomas S. 1668 S. GARFIELD AVENUE 2ND FLOOR ALHAMBRA, CA 91801	X		Chief Executive Officer					

Signatures

/s/ by Kirk Moon as attorney-in-fact for Thomas Lam, M.D.	06/13/2019	
**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Tin Kin Lee, Kirk L. Moon III, and Omar Dabuni, or any of them signing singly, and with full power of substitution, as the undersigned's true and lawful attorney-in-fact to:

- 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 13 and Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
- 2. execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or shareholder of Apollo Medical Holdings, Inc. (the "Company"), any Schedule 13D, Schedule 13G, and Forms 3, 4 and 5, and any and all amendments thereto, in accordance with Section 13 and Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Schedule 13D, Schedule 13G, and Forms 3, 4 and 5, to complete and execute any amendment or amendments thereto, and to file or cause to be filed such forms and amendments with the SEC and, to the extent required, with any stock exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of each such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by each such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as each such attorney-in-fact may approve in each such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and revocation, hereby ratifying and confirming all that each such attorney-in-fact, or each such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 13 and Section 16(a) of the Securities Exchange Act of 1934, as amended.

The undersigned agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to each such attorney-in-fact. The undersigned also agrees to indemnify and hold harmless the Company and each such attorney-in-fact against any losses, claims, damages or liabilities (or actions in these respects) that arise out of or are

based on any untrue statement or omission of necessary facts in the information provided by the undersigned to each such attorney-in-fact for purposes of executing, acknowledging, delivering and filing Schedule 13D, Schedule 13G, or Forms 3, 4 or 5 (including amendments thereto) and agrees to reimburse the Company and each such attorney-in-fact for any legal or other expenses reasonably incurred in connection with investigating or defending against any such loss, claim, damage, liability or action.

The powers granted pursuant to this Power of Attorney shall remain in full force and effect with respect to each attorney-in-fact until the earliest to occur of (a) revocation in writing by the undersigned, (b) resignation in writing by such attorney-in-fact, (c) the undersigned being no longer subject to Section 13 or Section 16(a) with respect to the Company's securities, and (d) such attorney-in-fact ceasing to provide legal representation to the Company. Notwithstanding the termination of this Power of Attorney with respect to one or more attorneys-in-fact, this Power of Attorney shall remain in full force and effect with respect to the remaining attorneys- in-fact. The execution of this Power of Attorney shall not of itself rescind or revoke any Power of Attorney granted by the undersigned to any other person.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as offebruary 27, 2019.

/s/ Thomas Lam, M.D. Thomas Lam, M.D., Co-Chief Executive Officer